Clinical and pathological features of acute optic neuritis in Chinese patients

Chinese Medical Journal

Volumn 126, Issue 9, 2013, Pages 1689-1692

  Zhang, Jia Ying ^a   Shen, Xu Zhong ^a   Sun, Li ^a   Lu, Zhao Zeng ^a   Ye, Wen ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Demyelinating diseases; Multiple sclerosis; Neuromyelitis optica; Optic neuritis

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISONE; RHEUMATOID FACTOR;

ADOLESCENT; ADULT; CLINICAL ARTICLE; FEMALE; HORMONE DETERMINATION; HUMAN; INCIDENCE; MALE; MEDICAL RECORD; MYELOOPTIC NEUROPATHY; NEUROIMAGING; OPHTHALMOLOGY; OPTIC NEURITIS; OUTCOME ASSESSMENT; PATHOLOGY; PATHOPHYSIOLOGY; PROLACTIN BLOOD LEVEL; RETROSPECTIVE STUDY; REVIEW; SINGLE DRUG DOSE; TESTOSTERONE BLOOD LEVEL; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT;

ACUTE DISEASE; ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; OPTIC NEURITIS; SEX CHARACTERISTICS; VISUAL ACUITY; VISUAL FIELDS; YOUNG ADULT;

EID: 84876937919     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20123599     Document Type: Review

References (23)

1. Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol 2004; 137: 77-83.
2. Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW. Visual field profile of optic neuritis a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. Arch Ophthalmol 2010; 128: 330-337.
3. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991; 109: 1673-1678.
4. de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol 2006; 90: 551-554.
5. Hutchinson WM. Acute optic neuritis and prognosis for multiple-sclerosis. J Neurol Neurosur Psychiat 1976; 39: 283-289.
6. Nikoskelainen E. Symptoms, signs and early course of optic neuritis. Acta Ophthalmol 1975; 53: 254-272.
7. Siva A, Kesselring J, Thompson AJ. Frontiers in multiple sclerosis 1999; 2: 37-46.
8. Weinshenker BG. Neuromyelitis optica: what it is and what it might be. Lancet 2003; 361: 889-890.
9. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
10. Foster SC, Daniels C, Bourdette DN, Bebo BF. Dysregulation of the hypothalamic-pituitary-gonadal axis in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neuroimmunol 2003; 140: 78-87.
11. Darlington C. Multiple sclerosis and gender. Curr Opin Investig Drugs 2002; 3: 911-914.
12. Gold R, Linington C. Devic's disease: bridging the gap between laboratory and clinic. Brain 2002; 125: 1425-1427.
13. Bergamaschi R, Tonietti S, Franciotta D, Candeloro E, Tavazzi E, Piccolo G, et al. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations. Mult Scler 2004; 10: 2-4.
14. Milano E, Di Sapio A, Malucchi S, Capobianco M, Bottero R, Sala A, et al. Neuromyelitis optica: importance of cerebrospinal fluid examination during relapse. Neurol Sci 2003; 24: 130-133.
15. Zaffaroni M. Cerebrospinal fluid findings in Devic's neuromyelitis optica. Neurol Sci 2004; 25: S368-S370.
16. Soderstrom M, Ya-Ping J, Hillert J, Link H. Optic neuritis - prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998; 50: 708-714.
17. Cole SR, Beck RW, Moke PS, Kaufman DI, Tourtellotte WW. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Neurology 1998; 51: 885-887.
18. Tumani H, Tourtellotte WW, Peter JB, Felgenhauer K. Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. J Neurol Sci 1998; 155: 44-49.
19. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130: 1235-1243.
20. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Establisbment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006; 210: 307-313.
21. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
22. Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, Palace J, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68: 1076-1077.
23. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70: 2197-2200.